文献速递脊柱关节炎

欧洲中轴型脊柱关节炎患者使用第二和第三种肿瘤坏死因子抑制剂:有效性与换药原因的影响

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究汇总12个欧洲登记处的常规诊疗数据,纳入8254个第二和2939个第三TNFi系列,评估12个月药物留存率和6个月ASDAS-ID缓解率。第二与第三TNFi的12个月留存率相似(71%),但第三TNFi的6个月缓解率(16%)低于第二TNFi(23%);第二TNFi因不良事件换药者的缓解率(27%)高于因疗效不足换药者(17%),第三TNFi则无此差异。

要点

  • 第二与第三TNFi的12个月药物留存率均为71%。
  • 第二TNFi的6个月ASDAS-ID缓解率为23%,高于第三TNFi的16%。
  • 第二TNFi因不良事件换药者6个月缓解率27%,高于因疗效不足换药者的17%。

核心结论

  • 中轴型脊柱关节炎患者使用第二和第三TNFi一年后留存比例相似,但第三TNFi缓解率低;第二TNFi(而非第三TNFi)在因不良事件而非疗效不足换药时缓解率更高。

研究设计与样本

  • 前瞻性收集的12个欧洲登记处常规诊疗数据汇总分析,纳入8254个第二TNFi系列和2939个第三TNFi系列。

主要发现

  • 12个月药物留存率在第二和第三TNFi系列相似(71%)。
  • 6个月ASDAS-ID缓解率第二TNFi为23%,高于第三TNFi的16%。
  • 因不良事件 vs 疗效不足停用前一种TNFi者,第二TNFi的12个月留存率分别为68%和67%,第三TNFi均为68%。
  • 第二TNFi中,原发性无应答者(疗效不足<26周)12个月留存率58%,低于继发性无应答者(疗效不足≥26周)的71%,P < 0.001。
  • 第二TNFi因不良事件换药者6个月ASDAS-ID缓解率为27%,高于因疗效不足换药者的17%,P < 0.001;第三TNFi两者分别为19%和13%,P = 0.20。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)]. METHODS: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission [Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)] were assessed in second and third TNFi-series and stratified by withdrawal reason. RESULTS: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE vs LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE <26 vs ≥26 weeks) (58% vs 71%, P < 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) vs LOE (17%), P < 0.001, while similar for the third TNFi (19% vs 13%, P = 0.20). CONCLUSION: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE vs LOE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Linde L, Ørnbjerg LM, Heegaard Brahe C, et al. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford). 2024. PMID: 37738257. doi:10.1093/rheumatology/kead494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。